NCT01979445

Cangrelor to Clopidogrel or Prasugrel Transition Study

A Study of the Transition From Cangrelor to Clopidogrel or Prasugrel in Patients With Coronary Artery Disease.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: The Medicines Company · Industry
• Sex: All
• Age: 18 Years – 74 Years
• Healthy volunteers: Not accepted

Summary

There are two separate objectives in this study: 1. To demonstrate the pharmacodynamic (PD) profile when participants treated with cangrelor are switched to oral prasugrel 60 mg administered 30 minutes (min) after cangrelor infusion is discontinued 2. To demonstrate the PD profile when participants treated with cangrelor are switched to oral clopidogrel 600 mg administered during or immediately after cangrelor infusion.

Conditions

• Coronary Artery Disease (CAD)

Interventions

Type	Name	Description
DRUG	Cangrelor	Cangrelor intravenously (IV) administered as a 30 microgram (µg)/kilogram (kg) bolus, followed by 4 µg/kg/min infusion for 2 hrs on Day 1.
DRUG	Clopidogrel	Clopidogrel 600 mg single oral dose
DRUG	Prasugrel	Prasugrel 60 mg single oral dose

Timeline

• Start date: 2013-12-02
• Primary completion: 2014-01-20
• Completion: 2014-01-20
• First posted: 2013-11-08
• Last updated: 2020-02-26
• Results posted: 2018-03-05

Locations

1 site across 1 country: United States